The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
As of 2025, Biden was the oldest sitting president in U.S. history. His cognitive health was perceived to have declined by Republicans and some media figures, and privately by some Democrats. Members of Biden's family and White House staffers insulated Biden from scrutiny of his advanced aging and decline in acuity. The media widely covered public concern about Biden's mental acuity after a weak performance in a June 2024 presidential debate, but gave it limited coverage beforehand, in part due to harsh pushback from White House officials. Biden initially deemed himself fit to serve two terms as president, but after the 2024 election said that he may have been too old to serve a second term. As part of the investigation into Biden's handling of classified documents, special counsel Robert Hur said that Biden did not remember when he was vice president ("if it was 2013—when did I stop being vice president?") or when his son Beau died. Hur wrote that his memory "appeared to have significant limitations". On July 21, 2022, Biden tested positive for COVID-19 with reportedly mild symptoms. According to the White House, he was treated with Paxlovid. He worked in isolation in the White House for five days and returned to isolation when he tested positive again on July 30. On July 17, 2024, Biden again tested positive for COVID-19.
Antipsychotics, previously known as neuroleptics and major tranquilizers, are a class of psychotropic medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia but also in a range of other psychotic disorders. Together with mood stabilizers, they are also a mainstay in the treatment of bipolar disorder. Moreover, they are also used as adjuncts in the treatment of treatment-resistant major depressive disorder. The use of antipsychotics may result in many unwanted side-effects, such as involuntary movement disorders, gynecomastia, impotence, weight-gain and metabolic syndrome. Long-term use can produce adverse effects, such as tardive dyskinesia, tardive dystonia, tardive akathisia, and brain-tissue volume-reduction. Withdrawal from antipsychotics can cause insomnia, tremors, and psychotic symptoms. First-generation antipsychotics (e.g., chlorpromazine, haloperidol, etc.), known as typical antipsychotics, were first introduced in the 1950s, and others were developed until the early 1970s. Second-generation antipsychotics, known as atypical antipsychotics, arrived with the introduction of clozapine in the early 1970s followed by others (e.g., risperidone, olanzapine, etc.). Both generations of medication block receptors in the brain for dopamine, but atypicals block serotonin receptors as well. Third-generation antipsychotics, introduced in the 2000s, offer partial agonism, rather than blockade, of dopamine receptors.
=== Organic chemistry research === Oleum is a harsh reagent, and is highly corrosive. One important use of oleum as a reagent is the secondary nitration of nitrobenzene. The first nitration can occur with nitric acid in sulfuric acid, but this deactivates the ring towards further electrophilic substitution. A stronger reagent, oleum, is needed to introduce the second nitro group onto the aromatic ring.
By contrast, the Biden administration's 2022 Review, while prioritizing Ground-based Midcourse Defense, emphasized that it is "neither intended nor capable of defeating" peer-level threats from Russia or China, noting "the interrelationship between strategic offensive arms and strategic defensive systems." While terrestrial defenses developed, the vision of a full space-based shield remained a consistent goal for its proponents. The modern groundwork for the Golden Dome was laid in 2017 by the SDI's former Deputy of Technology, and prominent Team B leader, Michael D. Griffin, who formed the Space Development Agency during the first Trump administration. Griffin long advocated for reusable launch vehicles to make the mass launching of weapons into space economically feasible. While the original Strategic Defense Initiative's attempts at this were short-lived, with the DC-X failing after a series of test flights, Griffin later encouraged and promoted funding of commercial reusable launch vehicles, which have since proven successful. The Heritage Foundation's Project 2025 effort advocated for a Golden Dome-like effort, writing that SpaceX's development of Starlink proves the feasibility of a space-based "overlayer" of thousands of networked satellites and interceptors, broadly similar to the Brilliant Pebbles concept of the 1980s. During his 2024 presidential campaign, Trump repeatedly mentioned the missile shield concept, often to mixed reception.
== Origin and evolution of RNA editing == The RNA-editing system seen in the animal may have evolved from mononucleotide deaminases, which have led to larger gene families that include the apobec-1 and adar genes. These genes share close identity with the bacterial deaminases involved in nucleotide metabolism. The adenosine deaminase of E. coli cannot deaminate a nucleoside in the RNA; the enzyme's reaction pocket is too small for the RNA strand to bind to. However, this active site is widened by amino acid changes in the corresponding human analog genes, APOBEC1 and ADAR, allowing deamination. The gRNA-mediated pan-editing in trypanosome mitochondria, involving templated insertion of U residues, is an entirely different biochemical reaction. The enzymes involved have been shown in other studies to be recruited and adapted from different sources. But the specificity of nucleotide insertion via the interaction between the gRNA and mRNA is similar to the tRNA editing processes in the animal and Acanthamoeba mitochondria. Eukaryotic ribose methylation of rRNAs by guide RNA molecules is a similar form of modification. Thus, RNA editing evolved more than once. Several adaptive rationales for editing have been suggested. Editing is often described as a mechanism of correction or repair to compensate for defects in gene sequences. However, in the case of gRNA-mediated editing, this explanation does not seem possible because if a defect happens first, there is no way to generate an error-free gRNA-encoding region, which presumably arises by duplication of the original gene region.
Sources: en.wikipedia.org
Following Alice in Chains' extensive 1993 world tour, Staley said the band "just wanted to go into the studio for a few days with our acoustic guitars and see what happened." "We never really planned on the music we made at that time to be released. But the record label heard it and they really liked it. For us, it was just the experience of four guys getting together in the studio and making some music." Columbia Records released Alice in Chains' second acoustic-based EP, Jar of Flies, on January 25, 1994. Written and recorded in one week, Jar of Flies debuted at number one on the Billboard 200, becoming the first EP—and first Alice in Chains release—to top the charts. Paul Evans of Rolling Stone called the EP "darkly gorgeous", and Steve Huey said, "'Jar of Flies' is a low-key stunner, achingly gorgeous and harrowingly sorrowful all at once." Jar of Flies features Alice in Chains' first number-one single on the Mainstream Rock charts, "No Excuses". The second single, "I Stay Away", reached number ten on the Mainstream rock charts, while the final single "Don't Follow", reached number 25. Jar of Flies has been certified triple platinum by the RIAA, with over 2 million copies sold in the United States during its first year. Jar of Flies received two Grammy nominations, Best Hard Rock Performance for "I Stay Away", and Best Recording Package. After the release of Jar of Flies, Staley entered rehab for heroin addiction.
The 2012 Colombian peace process refers to the dialogue in Havana, Cuba between the Colombian government and the FARC-EP to find a political solution to the armed conflict. After almost four years of peace negotiations, the Colombian state and the FARC announced consenus on a 6-point plan towards peace and reconciliation. The government also began a process of assistance and reparation for victims of the conflict. Recently, U.P. supporters reconstituted the political party within the reconciliation process. Colombia's congress approved the revised peace accord. In February 2015, the Historical Commission on the Conflict and its Victims (Comisión Histórica del Conflicto Armado y sus Víctimas – CHCV) published a report entitled "Contribution to an Understanding of the Armed Conflict in Colombia." The document addresses the "multiple reasons for the conflict, the principle factors and circumstances that made it possible, and the most notable impacts on the population", and explains Colombia's armed conflict in terms of international law.
== Function and pathology == Lp(a) is assembled at the hepatocyte cell membrane surface, which is similar to typical LDL particles. However, there are other possible locations of assembly. The particles mainly exist in plasma. Lp(a) contributes to the process of atherogenesis. The structure of apolipoprotein(a) is similar to plasminogen and tPA (tissue plasminogen activator), and it competes with plasminogen for its binding site, leading to reduced fibrinolysis. Also, because Lp(a) stimulates secretion of PAI-1, it leads to thrombogenesis. It also may enhance coagulation by inhibiting the function of tissue factor pathway inhibitor. Moreover, Lp(a) carries atherosclerosis-causing cholesterol and binds atherogenic pro-inflammatory oxidised phospholipids as a preferential carrier of oxidised phospholipids in human plasma, which attracts inflammatory cells to vessel walls and leads to smooth muscle cell proliferation. Moreover, Lp(a) also is hypothesised to be involved in wound healing and tissue repair by interacting with components of the vascular wall and extracellular matrix. Apo(a), a distinct feature of the Lp(a) particle, binds to immobilized fibronectin and endows Lp(a) with the serine-proteinase-type proteolytic activity. Nonetheless, individuals without Lp(a) or with very low Lp(a) levels seem to be healthy. Thus, plasma Lp(a) is not vital, at least under normal environmental conditions.
In general, polypeptides are unbranched polymers, so their primary structure can often be specified by the sequence of amino acids along their backbone. However, proteins can become cross-linked, most commonly by disulfide bonds, and the primary structure also requires specifying the cross-linking atoms, e.g., specifying the cysteines involved in the protein's disulfide bonds. Other crosslinks include desmosine.
light red or dark pink, being perfused with new capillary loops or "buds"; soft to the touch; moist; bumpy (granular) in appearance, due to punctate hemorrhages; pulsatile on palpation; painless when healthy;
Sources: en.wikipedia.org
The perichondrium (from Greek περί, peri, 'around' and χόνδρος, chondros, 'cartilage') is a layer of dense irregular connective tissue that surrounds the cartilage of developing bone. It consists of two separate layers: an outer fibrous layer and inner chondrogenic layer. The fibrous layer contains fibroblasts, which produce collagenous fibres. The chondrogenic layer remains undifferentiated and can form chondroblasts. Perichondrium can be found around the perimeter of elastic cartilage and hyaline cartilage. Perichondrium is a type of irregular collagenous ordinary connective tissue, and also functions in the growth and repair of cartilage. Perichondrium contains type I collagen and type XII collagen.
243Am(15N,xn)258−xNo (x=4) This reaction was studied in 1966 at the FLNR. The team were able to detect 250Fm using chemical techniques and determined an associated half-life significantly higher than the reported 3 s by Berkeley for the supposed parent 254No. Further work later the same year measured 8.1 MeV alpha particles with a half-life of 30–40 s.
== Interactions == valproic acid (Depakene, Stavzor) ganciclovir (Cytovene) probenecid (Benemid) penicillin antibiotics such as amoxicillin (Amoxil, Augmentin), ampicillin (Omnipen, Principen), dicloxacillin (Dycill, Dynapen), oxacillin (Bactocill), or phenoxymethylpenicillin (Beepen-VK, Ledercillin VK, Pen-V, Pen-Vee K, Pfizerpen, V-Cillin K, Veetids, and others); or cephalosporin antibiotics such as cefaclor (Ceclor), cefuroxime (Ceftin), cefadroxil (Duricef), cephalexin (Keflex), and others.
1926–1949: Commander of the 24th Army of the National Revolutionary Army 1927–1929: Commander of the Sichuan-Xikang Defence Force 1927–1934: Chairman of Sichuan Province 1934–1939: Chairman of the Xikang Provincial Establishment Committee 1939–1949: Governor of Xikang Province 1949–1954: Vice Chairman of the Southwest Military and Political Committee 1949–1976: Member of the National Committee of the Chinese People's Political Consultative Conference 1949–1976: Member of the National People's Congress 1954–1976: Member of the Central Committee of the Revolutionary Committee of the Chinese Kuomintang 1959–1967: Minister of Forestry of the People's Republic of China
In multiple electrode aggregometry, anticoagulated whole blood is mixed with saline and a platelet agonist in a single-use cuvette with two pairs of electrodes. The increase in impedance between the electrodes as platelets aggregate onto them, is measured and visualized as a curve.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.